Paul Sorajja, MD, discusses the late-breaking TRILUMINATE pivotal trial at ACC.23 and how tricuspid TEER performed against the current standard of care using medical therapy.

New research presented at the American College of Cardiology’s annual meeting has shown that long-term intermittent fasting improved outcomes for individuals with COVID-19 who also have a history of heart disease.

Here are links to more information on every late-breaking presentation at ACC.23.

ACC.23 Program Chair Doug Drachman, MD, explains what he saw as some of the key takeaways from the American College of Cardiology (ACC) 2023 annual meeting.

For patients who were hospitalized, but not yet in the ICU, those randomly assigned a higher-dose of anticoagulants had lower 30-day mortality risk than those on a lower dose. 

A team of cardiologists and radiologists collaborated on the study, using advanced imaging to take a closer look at the long-term impact of vaccination. 

Even among people who do not experience any major cardiovascular events, researchers noted, there are strong associations between poor mental health and poor heart health.

Researchers examined data from more than 700 TAVR patients, publishing their findings in the American Journal of Cardiology.

SCAI and the Association of Black Cardiologists have joined forces to share a simple message: PAD patients would be negatively impacted by new CMS proposals. 

SGLT2 inhibitors such as dapagliflozin and empagliflozin are associated with improved outcomes among many heart failure patients. The medications are not cost-effective, however, limiting their overall value. Read the full economic analysis to learn more.